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Health Policy

Primary stroke prevention worldwide: translating evidence
into action
Mayowa O Owolabi*, Amanda G Thrift, Ajay Mahal, Marie Ishida, Sheila Martins, Walter D Johnson, Jeyaraj Pandian, Foad Abd-Allah,
Joseph Yaria, Hoang T Phan, Greg Roth, Seana L Gall, Richard Beare, Thanh G Phan, Robert Mikulik, Rufus O Akinyemi, Bo Norrving,
Michael Brainin, Valery L Feigin*, on behalf of the Stroke Experts Collaboration Group†

Stroke is the second leading cause of death and the third leading cause of disability worldwide and its burden is
increasing rapidly in low-income and middle-income countries, many of which are unable to face the challenges it
imposes. In this Health Policy paper on primary stroke prevention, we provide an overview of the current situation
regarding primary prevention services, estimate the cost of stroke and stroke prevention, and identify deficiencies in
existing guidelines and gaps in primary prevention. We also offer a set of pragmatic solutions for implementation of
primary stroke prevention, with an emphasis on the role of governments and population-wide strategies, including
task-shifting and sharing and health system re-engineering. Implementation of primary stroke prevention involves
patients, health professionals, funders, policy makers, implementation partners, and the entire population along the
life course.

Lancet Public Health 2022;
7: e74–85

Introduction

*Contributed equally

The burden of stroke is a huge public health issue of
growing importance. In 2019, stroke was the second
leading cause of death (6·6 million people) and disability
(143 million disability-adjusted life years lost [DALYs])
worldwide.1 During the past three decades, in absolute
terms, global stroke incidence increased by 70%, its
prevalence increased by 85%, its mortality increased
by 43%, and DALYs due to stroke increased by 32%, with a
greater increase in stroke burden in low-income and
middle-income countries (LMICs) than in high-income
countries (HICs).1 From 1990 to 2019, there was a
37% global increase in the total number of stroke-related
DALYs due to risk factors, with LMICs disproportionately
affected.1 Stroke-related DALYs attributable to risk factors
increased by 48% in LMICs and declined by 25% in HICs
between 1990 to 2019.1 In 2019, the five leading risk factors
of stroke were high systolic blood pressure, high body-mass
index, high fasting plasma glucose concen
trations,
ambient particulate matter (PM2·5) pollution, and smoking.1
In 2011, the UN resolution2 and the WHO Global
NCD Action Plan 2013–203 called on all governments to
give primary prevention of non-communicable diseases
(NCDs), including stroke, the highest priority of all
diseases. The goal set by the UN resolution2 and the WHO
Global NCD Action Plan 2013–203 for countries was to
achieve a 25% reduction in their NCD-related burden by
2025.2,3 However, as stated by the UN Secretary-General
in 2017,4 the current level of progress on the prevention
and control of NCDs is insufficient to meet this goal.
The already enormous and continuously growing
burden of stroke presents several challenges. Although
LMICs bear most of the burden, they have only a small
share of the global financial and health-care resources.5
Strokes also occur about 15 years earlier among
individuals in LMICs than in HICs,6 leading to a marked
negative impact on socioeconomic development as
people in LMICs are most affected at the peak of their
productive lives.7 Additionally, despite the currently
www.thelancet.com/public-health Vol 7 January 2022

available knowledge of evidence-based interventions for
stroke prevention, this knowledge has not been translated
into reduced stroke burden in LMICs due to barriers
limiting implementation.8
The growing burden of stroke across the globe strongly
suggests that current primary stroke and cardiovascular
disease prevention strategies are either not used widely
enough or are insufficiently effective. Comprehensive
reviews of primary and secondary prevention of stroke9,10
have mostly focused on individual risk factors and
measurements of the effectiveness of preventive inter
ventions. This Health Policy paper is based on a multi
faceted approach, including a critical review of existing
primary prevention strategies and current guidelines,
economic analysis, and identification of gaps in primary
stroke prevention. This approach enabled us to provide
evidence-based pragmatic solutions on strategies for
primary stroke prevention within a cost framework that
global, regional, and national policy makers can use to
reduce the burden of stroke across the globe, especially
in LMICs. To derive these solutions (see appendix
pp 21–22, we used four steps, with the first two steps
described in detail and published elsewhere.11,12 We
conducted a situational evaluation by collecting and
analysing data on the state of stroke-related services and
resources in LMICs compared with HICs.11,12 Priority
setting was then done by extracting the highest grade of
evidence-based recommendations, as identified from a
systematic review of all available stroke guidelines across
the globe.12 We derived the barriers and facilitators for
implementing these recommendations in the context of
LMICs from situational evaluation and relevant literature
review (table 1 and table 2). Finally, we devised a roadmap
for primary prevention and pragmatic solutions were
proffered to implement evidence-based recommen
dations to reduce the burden of stroke in LMICs and
other underserved settings.
In this Health Policy paper, we aimed to: provide an
understanding of the burden and cost of stroke and the
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Goals

Targets

Recommendations and actions

Scarcity of funding for
primary stroke
prevention across all
countries, particularly in
LMICs

To provide sufficient
funding for primary and
secondary stroke
prevention

Governments and
politicians

Encourage all governments and politicians to reinvest revenues The proportion of funding allocated to
primary stroke prevention
from taxation on unhealthy products (eg, tobacco, sugary
drinks, alcohol, and salt in processed foods, aimed at reducing
consumption) back into health services and preventive
strategies; all health-care policy makers should be aware that,
for every US$1 spent on prevention of stroke and cardiovascular
disease, there are over $10 returns on investment

Assessment methods

Few countries or regions
have established action
plans for stroke
prevention

To establish countryspecific action plans and
stroke prevention
guidelines for every
country

The whole population for
population-wide
prevention strategies and
individuals at any level of
risk for individual
prevention strategies

All governments should allocate sufficient funding for the
development and implementation of primary stroke prevention
strategies, have financially sustainable action plans for primary
and secondary stroke prevention, and should have culturally
appropriate guidelines for primary and secondary stroke
prevention; adults are encouraged to use freely available and
validated mobile phone apps for managing their risk factors
(eg, WSO, World Heart Federation, World Federation of
Neurology, and European Stroke Organisation recommended
Stroke Riskometer app); transferring and sharing tasks of primary
stroke prevention from highly trained health professionals to less
qualified health-care workers after training; culturally appropriate
education about healthy lifestyles should be incorporated into
standard education curricula and started early in life, with
reinforcement across the lifespan

Stroke incidence, mortality, and disability;
prevalence of risk factors; 5 or 10 year risk
of cardiovascular disease and stroke;
availability of stroke and transient
ischaemic attack and stroke prevention
clinics; proportion of people at risk of
stroke and people who have had a stroke
or transient ischaemic attack managed in
clinics; proportion of evidence-based
decisions in stroke prevention

Absence of an integrative
approach in primary
stroke prevention,
particularly in LMICs

To establish collaboration National and
between different national international agencies
and international agencies and organisations
and organisations involved
in primary prevention of
non-communicable
disease

Include nationally and internationally recognised stroke experts
in all relevant national and international agencies and
organisations involved in primary prevention of
non-communicable diseases; prioritise primary stroke
prevention strategies to reduce exposure to cardiovascular
disease risk factors in the whole population across the life
course, including intrauterine life, with a focus on optimal
maternal and child health care, behavioural, and lifestyle risk
factors, which would enable an integrative approach that also
targets other non-communicable diseases (eg, dementia,
diabetes, cancer, and pulmonary diseases)

Checklist of representation of stroke
experts in all relevant national and
international agencies and organisations
involved in primary prevention of
non-communicable diseases

Little stroke awareness
across all countries

To establish national
ongoing stroke awareness
campaigns about stroke,
its warning signs, and its
prevention

The whole population

All national and regional stroke organisations should conduct
ongoing stroke awareness campaigns about stroke, its warning
signs, and its prevention, coordinated by the WSO; regular
television programmes are the preferred channel of media for
such campaigns

Stroke awareness surveys

Absence of monitoring
systems for evaluation of
the effectiveness of
preventive strategies

To establish national and
subnational (for large
countries) monitoring
frameworks

Whole population and
people at risk of stroke

All countries should have monitoring systems to evaluate the
effects of primary and secondary prevention strategies; in the
absence of sufficient quality country-specific epidemiological
data on burden of stroke and risk factors, health-care policy
makers should be encouraged to use relevant Global Burden of
Disease estimates; regular use of accurate data to support
decision making

Changes in the 5 year or 10 year absolute
risk of stroke and cardiovascular disease of
outpatients; strengthening surveillance for
key stroke risk factors (eg, increased blood
pressure, smoking, alcohol, obesity,
and excessive salt consumption) with use
of regular (eg, once in 2–5 years)
inexpensive population-based surveys
(eg, WHO STEPwise survey) would provide
policy makers with accurate estimates of
prevalence of stroke risk factors to
prioritise investments to reduce exposure
to the risk factors and reduce the incidence
and burden of stroke; ongoing or regular
(eg, once in 2–5 years) registries of strokes
morbidity and mortality

Insufficient funding of
stroke prevention
research across all
countries, particularly in
LMICs

To study determinants of
stroke occurrence and
outcomes and the best
strategies to reduce
stroke burden

Health research funding
agencies

In consultation with recognised regional experts on stroke and
public health, allocate sufficient funding for research in primary
and secondary stroke prevention

Proportion of research funding allocated
to primary stroke prevention (compared
with the total health research funding)

LMICs=low-income and middle-income countries. WSO=World Stroke Organization.

Table 1: 2021–30 primary stroke prevention roadmap

College Hospital, Ibadan,
Nigeria (J Yaria MSc); Menzies
Institute for Medical Research,
University of Tasmania,
Hobart, TAS, Australia
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evidence
primary
overview
lines for

for the cost-effectiveness of the existing
stroke prevention strategies; provide an
of available strategies, services, and guide
primary prevention of stroke and identify

deficiencies and gaps in primary stroke prevention;
and provide a set of pragmatic solutions for policy
makers, funding organisations, and other stakeholders
for funding and implementation of primary stroke
www.thelancet.com/public-health Vol 7 January 2022
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Level of evidence*

Resources required for
implementation

Ethical, legal, and social implications and Recommendation for contextualisation and
barriers and facilitators
implementation through policy makers and other
activities

Countries should have
government-endorsed policies
for community-wide stroke
prevention3,13–17

Level B evidence that
tobacco, salt, and alcohol
taxation is an effective
strategy to improve health;
level A evidence for
population-wide primary
stroke and other
non-communicable disease
prevention

Expertise in stroke and
cardiovascular disease
epidemiology and
public health

Industry lobbying (eg, for reducing salt
content in processed food, and reducing
consumption of sugary drinks and alcohol);
absence of expertise to develop an efficient
action plan and community support for
introducing taxation on salt, sugary drinks,
alcohol, and tobacco products; government
and health policy engagement; public
resources for accessible and affordable
healthy food outlets, physical activity
facilities, and healthy ecological
environment

Policy makers and health experts to develop legislative
changes for reducing salt content in processed food and
reducing consumption of sugary drinks and alcohol,
including the development of policies for communitywide stroke prevention activities, monitoring the
effectiveness of prevention activities, and health-care
workforce development; reinvestment of taxation
revenue into primary and secondary prevention, health
service development, and health research; health
ministry order for public health services; developing and
regularly (at least every 5 years) updating national
primary stroke prevention guidelines; reinvestment of
taxation revenue into the development of accessible
and affordable healthy food outlets, physical activity
facilities, and reducing air pollution

Countries should have ongoing
stroke awareness and
prevention campaigns and
interventions18–27

Level B evidence; WHO One
Health initiative; level A
evidence for control of risk
factors for stroke
prevention; level A evidence
for use of polypill for blood
pressure and cholesterol
reduction

Expertise in
development and
maintenance of
awareness campaigns;
electronic patient
management systems

Barriers include scarcity of engagement of
stakeholders (eg, patients, providers, and
policy makers); absence of collaboration
between multiple sectors of society (eg,
government, public health, and research
and education)

Policy makers and health experts to develop strategies
and action plans for ongoing stroke awareness and
primary prevention, with a strong emphasis in LMICs on
early detection and management of increased blood
pressure and reduction of exposure to air pollution;
policy makers and health experts should develop a plan
for prioritising multisectoral and cost-effective
accessible and affordable interventions, including the
implementation of mobile technologies to promote a
healthy lifestyle and primary stroke prevention;
adequate education and regular antenatal care for
pregnant women (balanced and adequate nutrition for
pregnant women and infants are important primordial
measures to reduce the risk of stroke)

Countries should have a
nationwide and representative
system for measuring and
monitoring the effects of
primary prevention activities
(eg, absolute risk of stroke and
cardiovascular disease of the
population, stroke incidence,
and stroke mortality)27

Level B evidence

Expertise in
epidemiology,
data management,
and statistics to support
ongoing monitoring
of stroke

Barriers include absence of infrastructure to
support a monitoring programme;
expertise to develop an efficient
programme; capacity to analyse the data
collected and produce quality statistics; and
data use to drive decision making

Policy makers and health experts to develop,
implement, and monitor a reliable, simple, and fit-forpurpose strategic action plan with all stakeholders to
ensure the availability of standardised surveillance
systems for stroke and risk factors in their countries
and regions

*Levels of evidence are randomised controlled trials (A), controlled trials with no randomisation (B), observational trials (C), and opinion of an expert panel (D).

Table 2: Evidence and pragmatic solutions for improving primary stroke prevention worldwide

prevention strategies, with examples of successful
translation of evidence into actions. To achieve the
aims of this paper, we structured the materials into
six sections. First, we provide an overview of the cost
of stroke and present the economic case for stroke
prevention. Second, we provide an analysis of epidemio
logical evidence and situational analyses for improving
primary prevention. Third, we provide an overview of
barriers and facilitators for the implementation of
primary stroke prevention guidelines and identify
deficiencies, gaps, and pragmatic solutions in primary
stroke prevention. Fourth, we describe joint efforts
required for improving primary stroke prevention and
justify the need for the establishment of regional
and national plans on stroke prevention. Fifth, we
present strategies for innovative dissemination and
implementation of the suggested solutions. Finally, we
define future directions in implementation and research
on primary stroke prevention.
www.thelancet.com/public-health Vol 7 January 2022

The cost burden of stroke and the economic case
for prevention
To develop an economic case for the pragmatic solutions
for the primary prevention of stroke, we measured the
global economic burden of stroke. The estimated economic
burden accounted for the global financial costs of providing
acute care to patients with stroke in hospital, including
rehabilitation, and in the post-acute phase, including
medical care, social services, and informal caregiving
(appendix pp 7–20). We also estimated the income losses
associated with people who have had a stroke and their
households due to premature death and disability, and we
estimated production losses as a result of stroke
(appendix pp 7–20). Data from the Global Burden of
Disease Study (GBD) 2017 on the number of new stroke
cases and deaths from stroke28 were combined with the
best available estimates of the costs of stroke treatment,
rehabilitation, social care, and informal caregiving
from 30 countries representing different income levels

(H T Phan PhD, S L Gall PhD);
Institute for Health Metrics
Evaluation (Prof G Roth MD),
and Institute for Health
Metrics Evaluation
(Prof V L Feigin PhD), University
of Washington, Seattle, WA,
USA; Developmental Imaging
Group, Murdoch Children’s
Research Institute, Melbourne,
VIC, Australia (Prof R Beare);
International Clinical Research
Center, Neurology
Department, St Anne’s
University Hospital, Masaryk
University, Brno, Czech
Republic (Prof R Mikulik PhD);
Department of Clinical
Sciences, and Department of
Neurology, Skåne University
Hospital, Lund University,
Lund, Sweden
(Prof B Norrving PhD);

e76

Health Policy

Department of Neuroscience
and Preventive Medicine,
Danube University Krems,
Krems an der Donau, Austria
(Prof M Brainin PhD); National
Institute for Stroke and
Applied Neurosciences, School
of Clinical Sciences, Faculty of
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Sciences, Auckland University
of Technology, Auckland,
New Zealand (Prof V L Feigin);
Scientific and Educational
Department, Research Centre
of Neurology, Moscow, Russia
(Prof V L Feigin)
Correspondence to:
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See Online for appendix
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(eg, Germany, the USA, the UK, Japan, China, Brazil,
Turkey, Cameroon, Thailand, and India). Our estimates
suggest that the global lifetime costs of treatment,
rehabilitation, social care, and informal caregiving are
international (I) $393 billion (or 0·3% of global gross
domestic product [GDP]), with a range from approximately
$206 billion (0·2% of global GDP) to $638 billion (0·5% of
global GDP) among new stroke cases in 2017. In addition
to direct costs, income losses due to incident stroke cases
from premature death and disability after stroke were
likely to be large, which has important welfare implications
for people who have had a stroke and their households. We
estimated that discounted lifetime economic losses to
households with incident stroke cases in 2017 were I$976
billion globally (0·77% of global GDP). Roughly a third of
the income losses to households with incident stroke
occurred in HICs and a half occurred in upper middleincome countries (MICs). Income losses from stroke in
lower MICs and lower-income countries (LICs) accounted
for only 15% of the global total, primarily because of their
much lower income levels than HICs and upper MICs.
However, these estimates are likely to be conservative
because they do not account for out-of-pocket costs and
income losses arising from the added responsibilities
falling upon caregivers who might have to give up paid
work. Using a friction cost approach, we estimated a lower
bound of I$58 billion in production losses. Overall, we
estimated that the total global direct and indirect costs of
stroke in 2017 were US$891 ($746–1077) billion (1·12%
[0·94–1·36%] of global GDP) or I$1369 ($1182–1614) billion
(appendix p 15).
Although large, our estimates of the global economic
burden of stroke cannot be directly compared with
existing global economic burden estimates for other
health conditions (eg, cancer,29 dementia,30 cardiovascular
disease,31 and heart failure32) owing to differences in
methods, especially relating to the issue of attribution of
costs to conditions from similar risk factors. A World
Economic Forum report in 2011 did provide comparable
estimates for the economic burden of different NCDs,
but did not include stroke.33 Given the average annual
growth rate of the global economy of approximately
3·5% during the past decade, our estimates of the
economic burden of stroke translates to at least 10% of
the annual addition to global wealth being devoted to
stroke. This economic burden, in addition to the
economic consequences to households directly affected
by stroke, shows major declines in the wellbeing of
people who have had a stroke and their households.
With the costs of stroke care, the economic gains from
interventions that can help reduce stroke incidence and
mortality by small numbers are potentially large. There is
a sufficient body of evidence to show that achieving
the UN Sustainable Development Goals (SDGs;34
appendix pp 20–21) and WHO health targets3 with low
costs (eg <US$1 per person a day [$0·43–0·90] in LICs
and <$3 a day [$0·54–2·93] in MICs)35,36 could reduce the

mortality rate for ischaemic heart disease and stroke
by 10%. In turn, economic losses in LMICs would be
reduced by an estimated US$25 billion per year.36,37
Another promising strategy to reduce stroke incidence
and mortality is to reprioritise health investment streams
towards population-wide primary prevention across the
lifespan. It has been estimated that, for every US$1 spent
on the prevention of stroke and cardiovascular disease,
there is a more than $10 return on investment and that
the preventive interventions focused on risk factors are
the most cost-effective options.38 Additionally, stroke
primary prevention efforts are likely to yield large gains
due to secondary effects of reducing the risk of heart
disease, type 2 diabetes, dementia, and some types of
cancer that share common risk factors, thus supporting
achievements of a range of SDGs.

Epidemiological evidence and situational
analyses for improving primary prevention
A World Stroke Organization coordinated international
survey on stroke11,12 showed that only about a third of the
recommended activities for primary prevention are being
done in the 82 countries that participated in the survey,
and the use of these recommended activities was
particularly poor in LICs. Although 81% of countries
reported that cardiovascular disease risk stratification was
offered at primary health-care facilities, the reported
availability of this service within these countries varied
widely. Although nearly half (38 of 82) of these countries
reported that risk stratification was available in more than
50% of health-care facilities, 29% reported that it was
available in less than 25% of facilities, and 15% reported
that it was available in between 25% and 50% of facilities.
Additionally, half of the countries (53%) reported general
availability of all six essential tests and procedures
(ie, measurement of height, weight, blood pressure, blood
glucose, and total cholesterol, and urine strips for albumin
assay).
Marked disparities were evident across the income
groups: 96% of HICs reported all six tests and procedures
were generally available compared with 16% of LICs.
Although many countries have a national strategy towards
a healthy diet, reducing tobacco use, and reducing
diabetes, only 42% of countries have national strategies
for all three issues and fewer than one in three countries
have smoke-free environments in all indoor workplaces,
public transport, and indoor public places.
There are two main primary stroke and cardiovascular
disease prevention strategies currently in use: populationwide cardiovascular disease strategies and strategies for
individuals who have high risk for cardiovascular disease.
Conventional screening of the population for people with
high risk of cardiovascular disease risk with various
prediction algorithms (eg, atherosclerotic cardiovascular
disease risk eval
uation39 or PREDICT algorithms40),
which categorise people into mild (ie, moderate), low, or
high cardio
vascular disease risk, does not motivate
www.thelancet.com/public-health Vol 7 January 2022
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Conventional population-wide prevention strategy
(optimal distribution of risk)
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Up to 90% stroke
incidence reduction
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Conventional population-wide prevention strategy
(optimal distribution of risk)
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80
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Present distribution of risk

40

Strategy for high-risk
cardiovascular
disease prevention

20

Up to 11% stroke
incidence reduction

0

C
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80
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people with low and mild cardiovascular disease risk to
reduce their risk.41 Therefore, the World Stroke
Organization and World Heart Federation, in their recent
joint position statement,42 recommended not to label
people with low and mild cardiovascular disease risk
when com
municating absolute cardiovascular disease
risk to patients. These screenings of the population for
high cardiovascular disease risk have been shown to be
ineffective to reduce stroke and ischaemic heart disease
incidence and mortality rates in randomised trials in
107 421 people (relative risk 1·05 [95% CI 0·95–1·17];
53%).18,43,44 Because of the need for a blood lipid test, and
the associated costs, these prediction tools have low
applicability in LMIC settings (until point-of-care devices
with low cost are available).41 Moreover, as stated by the
World Heart Federation and World Stroke Organization,42
these screening programmes might exa
cer
bate socio
economic inequalities45 and have potential hazards of
labelling people as low risk, giving them false reassurance
that they are protected from stroke and heart attack and
compromising any motivation to control risk factors.41,45,46
So-called high-risk prevention strategies are targeted
interventions for individuals at high risk of cardiovascular
disease that are usually implemented by health-care
professionals. Although these interventions might be
adequate for conditions confined to an identifiable
minority of people at high risk of cardiovascular disease,
most (up to 80%) of stroke and cardiovascular disease
arise from individuals at low risk,47–49 who not covered by
the high-risk prevention strategies.41 Issues for clinicians
in primary stroke prevention at the individual level
include the absence of digital decision-making tools19 and
scarcity of time to motivate, develop, and give tailored
primary prevention recommendations to the patient. An
example of a digital decision-making tool that can help to
resolve all these issues is the desk-top multilanguage
PreventS web app for clinicians, developed by the
Auckland University of Technology (appendix pp 22–27).
As the mean amount of exposure to causal risk factors
throughout the population correlates closely with the
incidence of stroke and cardiovascular disease in the
population, the population-based strategy of prevention
aims to reduce the mean amount, and overall distribution,
of exposure to causal risk factors throughout the population
to reduce the incidence of cardiovascular disease.50
Preliminary calculations suggest that, if population-wide
strategies were implemented widely and effectively, they
could prevent up to 50–90% of stroke and cardiovascular
disease events in 5 years.1,20,46,51 A motivational mass
prevention strategy via eHealth technologies52,53 in
combination with polypill and task-shifting, task-sharing
(or task transfer)46 could prevent up to 50% of stroke and
cardiovascular disease events. High-risk strategies can
potentially prevent about 11% of stroke and cardiovascular
disease events (figure 1).54 Both high-risk and populationwide strategies should complement each other,21,22 and
priority should be given to population-wide strategies.41,42

Conventional population-wide prevention strategy
(optimal distribution risk)
Motivational mass prevention strategy inclusing eHealth,
polypill, and task-shifting (eg, healthy volunteers)

60

Present distribution of risk

40
Up to 50% stroke
incidence reduction

20
0
Low to moderate risk

High risk

Figure 1: Optimal shift in the distribution of cardiovascular disease risks through a combination of
population-wide strategies for high-risk cardiovascular disease prevention
Areas shadowed in green show a theoretically possible proportion of the population that could benefit from
(A) a population-wide prevention strategy, (B) strategies for high-risk cardiovascular disease prevention, and
(C) a motivational mass individual risk prevention strategy regardless of the cardiovascular disease risk (ie, use of
mobile applications to reduce lifestyle and other risk factors). Modified from Feigin and colleagues, with permission.52

Guidelines and pragmatic solutions
Population-wide strategies for primary stroke and
cardiovascular disease prevention are well established
(eg, nationwide measures to reduce exposure to smoking
and vaping; reduce intake of sugary drinks, salt, and
alcohol; and promote adequate physical activity).3 These
population-wide strategies are recommended in several
international and WHO guidelines,35,55–57 but their
implementation is unacceptably slow and far from
universal.12 As shown in a systematic review of stroke
guidelines,12 there are two main reasons for slow
e78
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Panel: Key solutions for primary stroke prevention
Effective stroke prevention should include population-wide and individual-based strategies
that cover all, or most, of the population, with priority given to population-wide strategies.
Individual-based primary stroke prevention strategies can be best accomplished with
mobile phone technology (so-called motivational mass individual strategy for stroke
prevention),41 a simple and inexpensive screening for a history of cardiovascular disease
and presence of modifiable risk factors (particularly smoking and vaping, obesity,
and elevated blood pressure), linked to local, regional, or national electronic databases for
health care. These strategies for the individuals should be enhanced by the involvement
of health professionals who use similar motivational computer-based tools to
individualise stroke risk factor recommendations and monitor the effects of the
interventions among individuals. Individual-based strategies can also be accomplished
with shifting and sharing of tasks from highly trained health professionals to health-care
workers, particularly community-based health workers to facilitate stroke prevention
interventions on the individual. Examples of individual-based primary stroke prevention
strategies are those in selected populations of Finland,61 Japan,62 and the USA;63
the validated and free Stroke Riskometer app52,53,64 that is being used in 19 languages in
78 countries, potentially covering 5·3 billion people; the PreventS-MD web app for
clinicians;1 and the transferring and sharing of tasks from highly trained health
professionals to health-care workers implemented in several areas of India.65,66
Governments should provide adequate health services, improve socioeconomic
conditions, reduce inequities, and influence environmental (eg, air pollution) and lifestyle
factors (eg, smoking, vaping, reducing salt, sugar in processed foods, and alcohol intake
through legislation and taxation), and health systems should identify, screen, and manage
risk factors. Revenues from these taxations should be invested into the public health sector
and health research to improve the health of the taxpayers, including appropriate funding
of primary prevention strategies for stroke, cardiovascular disease, and other
non-communicable diseases. Governments have to be transparent about the proportion
of health budgets that are focused on prevention. Examples of population-wide strategies
include effective smoking cessation campaigns in some countries;13 taxation of sugary
drinks in several countries, including the UK, Ireland, France, Canada, South Africa,
United Arab Emirates, Portugal, Mexico, and Sri Lanka;14 junk food taxes in Mexico and
Hungary;15 successful alcohol reduction in Russia;16 and a successful air pollution campaign
in China.17 The effectiveness of the proposed primary stroke prevention measures should
be regularly assessed by monitoring stroke incidence, mortality, prevalence (ie, rates and
absolute numbers), and risk factors (ie, prevalence and changes in absolute and relative
risks of stroke and cardiovascular disease) at the individual and population levels. Examples
of such monitoring include the World Stroke Organization stroke survey,12 WHO health
survey,26 and the Global Burden of Disease Study.27

For more on the course on
global sodium reduction
strategies by Johns Hopkins
University see https://
resolvetosavelives.org/timeline/
new-online-course-on-globalsodium-reduction-strategies
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implementation of population-wide strategies. First, such
strategies require policy and legislative changes that are
often not supported by major industries (eg, salt reduction
in processed food and reduction of exposure to smoking,
alcohol, and fast food).23,58 According to the GBD
2019 estimates, poor and unhealthy diet, as defined by a
cluster of dietary risks, is associated with 30·5%
(95% uncertainty intervals 22·6–39·8) of stroke-related
DALYs.1 There is also evidence of the double burden of
low income and an unhealthy neighbourhood food
environment on objective measures of adiposity and its
contribution to social inequalities in health.24 Governments
should be responsible for, and seek strategies to reduce
the exposure of their citizens to, unhealthy food, and

should facilitate healthy diets and healthy fast food chains
as the distributors of snacks, dinners, and lunches.
Second, implementation of a full range of populationwide prevention strategies requires substantial invest
ments from governments and industry, and preferably
universal health coverage, including setting up affordable
and widely accessible health services, creating affordable
facilities for physical activity, and reducing air pollution
and socioeconomic inequalities. In addition, despite a
special 2011 NCDs UN declaration to have an NCD
prevention plan in every country,2 most countries still do
not have such a plan.
The majority of the burden of stroke (60–70%) across all
countries in the world is associated with elevated systolic
blood pressure (the single most important risk factor for
stroke) and unhealthy lifestyle risk factors, such as
smoking, obesity, low physical activity, and poor diet
(eg, excessive salt, sugar, and alcohol intake and low fruit
and vegetable consumption).1 A comprehensive review of
hypertension prevalence and treatment found that,
although the overall rate of hypertension in the world did
not change much from 1990 to 2019, the burden of
hypertension has shifted from HICs to LMICs and the
number of people with hypertension has doubled from
648 million in 1990 to 1·28 million since 1990.59 The new
WHO Guideline for the pharmacological treatment of
hypertension in adults60 provides recommendations on the
threshold for the initiation of pharmacological treatment
for hypertension (systolic blood pressure of ≥140 mm Hg
or diastolic blood pressure of ≥90 mm Hg in people with a
confirmed diagnosis of hypertension or systolic blood
pressure of 130–139 mm Hg in people with existing
cardiovascular disease, regardless of the absolute cardio
vascular disease risk) and recommendations on intervals
for follow-up, target blood pressure for control, and the
skill level of health-care workers who can initiate treatment.
Reducing exposure to these risk factors and treating
hypertension should be the priority targets for both
population-wide and individual-based preventive inter
ventions for primary stroke prevention (panel). A good
example of decisive actions to stop smoking is the suite of
proposals of the Government of New Zealand aimed at
creating a smoke-free generation and moving the country
closer to its goal of being smoke free by 2025. Step-by-step
action plans and online courses on global salt reduction
strategies for policy makers, advocates, and programme
managers have been developed to implement scalable
interventions focusing mainly on LMICs and are offered
for free by Johns Hopkins University. The medical
community must continue to advocate for governments to
implement evidence-based population-wide prevention
strategies.
On the basis of the totality of evidence the World Stroke
Organization has issued a Declaration46 that recommends
the use of four strategies for global primary prevention of
stroke and dementia: (1) population-wide policy strategies
to reduce exposure to risk factors (including environmental
www.thelancet.com/public-health Vol 7 January 2022
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risk factors such as air pollution) for stroke, dementia,
cardiovascular disease, and other NCDs across the lifespan
of the entire population regardless of the individual
cardiovascular disease risk; (2) motivational populationwide strategy that uses health apps (eg, the free Stroke
Riskometer app44,53,52,64) or apps to reduce lifestyle and other
risk factors in adults at any increased risk of stroke
(appendix pp 23–27); (3) targeted polypill (consisting of
two low-dose generic blood pressure-lowering medications
and one generic lipid-lowering medication) strategy for
adults older than 55 years at risk of cardiovascular disease
(ie, at least two behavioural or metabolic cardiovascular
disease risk factors); and (4) preventive strategies to control
behavioural risk factors (especially smoking and elevated
blood pressure) and diabetes via community health
workers (community health workers were also suggested
to facilitate implementation of the second and third
strategies).
As stated in the World Stroke Organization Declaration,46
policy makers and health providers should reduce exposure
to risk factors at a population level regardless of the
cardiovascular disease risk through mass approaches
(eg, smoking cessation campaigns, reducing salt and sugar
in processed food, and restricting alcohol consumption)
and more individual-focused motivational education about
behavioural risks (eg, poor diet, physical inactivity, alcohol
use, and smoking) via apps. In addition, simple inexpensive
screening for vascular risks (eg, elevated blood pressure,
smoking, and overweight or obesity)44 by community
health-care workers or people from stroke support
organisations (in resource-poor settings) or by medical
professionals (including use of blood lipid tests; in settings
with better resources) would identify individuals in need of
prophylactic drug therapy in conjunction with lifestyle and
behavioural interventions.41 There is also evidence of sex
differences in the risk of stroke1 and its risk factors67 and
evidence that the intensity of primary stroke prevention
should not be reduced as people age.68 These
recommendations are summarised in the 2021–30 primary
stroke prevention roadmap (table 1). With all these
recommendations implemented into practice, a similar
shift to that shown in figure 1 in the distribution of risk
factors would occur as with the population-wide primary
prevention strategy (figure 1).

Joint efforts and establishment of regional and
national plans
Stroke is a complex medical and socioeconomic issue.25,69,70
Therefore, the importance of global, international, and
national efforts and collaboration between various sectors
of health care, decision makers, government and
non-government agencies (eg, stroke, cardiovascular
disease, and NCD organisations), industry, communities,
and individuals for effective reduction of stroke burden
cannot be overemphasised (figure 2).9,71 Government
bodies have the power and responsibility to provide
adequate health services to cover primary prevention,
www.thelancet.com/public-health Vol 7 January 2022

improve socioeconomic conditions, reduce inequities,
and influence environmental (eg, reduction of air
pollution and building healthy cities) and lifestyle factors
(eg, reducing salt and sugar in processed food and alcohol
intake through legislation and taxation). Moreover, health
systems have responsibilities for identification and
management of risk factors and people with cerebro
vascular diseases, and government and non-government
organisations have responsibilities for ongoing public
(eg, stroke awareness days) and professional (eg, teaching
courses and conferences) education. In addition, inter
sectoral intervention is required to provide essential
medicines for primary stroke prevention (eg, affordable
blood pressure-lowering and lipid-lowering medications)
and an enabling environment for healthy lifestyles,
including reworking the food chain to make healthy
food available and affordable for all, providing safe
neighbourhoods conducive to walking, and ensuring
access to care. Another approach would be to change
public policy to enable community health workers to
distribute medicines prescribed by doctors. This approach
is particularly important in hard-to-reach regions where
there is little access to medical professionals. This type of
coordinated intervention allows interlinking communitywide prevention and individual management approaches
that improve health across the care continuum and across
settings and strategies (figure 2).72
The development and implementation of action plans
for primary stroke prevention should be aimed towards
achieving the internationally recommended goals and
targets for reducing the burden from NCDs.2,3 These
country-specific and financially sustainable action plans
and consensus statements need to be developed by
recognised local experts, based on evidence, and endorsed
by government agencies and should contain well
developed implementation plans that include key
performance indicators, steps, timelines, funding
(including funding for implementation), and accountable
people. These action plans should be facilitated by
national, culturally appropriate, and up-to-date guidelines
for primary stroke prevention. Unfortunately, there is a
shortage of operational national plans aligned with the
Global Action Plan for NCDs.73 Although there are several
national guidelines for primary stroke prevention in
HICs,55,74 there is a paucity of such evidence-based,
context-appropriate pragmatic guidelines in LMICs.9
Although mainstream preventive strategies should be
similar in HICs and LMICs, differences in the populationattributable risks, lifetime risk of stroke, distribution of
different risk factors, and availability of resources should be
considered when setting goals and priorities. For example,
given the much greater burden of smoking, air pollution,
and haemorrhagic stroke in LMICs than in HICs,75 a strong
emphasis on early detection and management of elevated
blood pressure, reduction of air pollution, and antismoking campaigns should be a priority in LMICs. This
priority should be facilitated by government-imposed
e80

Health Policy

Population-wide strategies

Improving socioeconomic
conditions and reducing poverty

Building healthy cities and homes

Individual strategies

Reducing inequities
and other social
determinants of
stroke and
cardiovascular
disease

Reducing air
pollution and
implementing
universal health
coverage

Affordable healthy
food and physical
activity facilities

Cardiovascular disease strategy for
identification and management of
people at high risk of
cardiovascular disease by clinicians
(primarily for blood pressure and
lipid lowering interventions)

Simple screening for vascular
risk factors (eg, increased
blood pressure, smoking, and
overweight)

Task-shifting and sharing (eg,
health volunteers) and
interlinked eHealth
technologies for the general
public and clinicians

Motivational culturally relevant
individual strategy for
identification and management of
people at risk of stroke or
cardiovascular disease (primarily
for healthy lifestyle management)
via eHealth technologies

Affordable medications
with a delivery system
that reaches the
population affected

Reducing tobacco
and alcohol use and
salt, sugar, and trans
fat consumption

Encouraging
healthy lifestyle
Regular stroke
awareness and risk
factors campaigns
and education

Figure 2: Action plan for governments and other policy makers for primary stroke prevention measures at the population (ie, socioeconomic, environmental,
and behavioural) and individual levels

measures to reduce sodium in processed food and increase
education of individuals about reducing salt and tobacco
intake.76 In addition, in HICs, where smoking prevalence
has reduced and the burden associated with ischaemic
stroke is noticeably higher than in LMICs, it seems
reasonable to focus more heavily on the reduction of other
behavioural risks (particularly on the reduction of sugar
consumption and physical inactivity) and on the
identification and pharmacological or surgical management
of medical conditions that lead to stroke, including
hypertension, diabetes, and atrial fibrillation. Populationwide and individual primary stroke and cardiovascular
disease prevention strategies,52 should be used regardless
e81

of the level of stroke or cardiovascular disease risk, with
priority given to population-wide strategies. In addition to
preventive strategies towards medical risk factors,
addressing social determinants of health (eg, poverty,
education, health insurance, social inclusion and nondiscrimination, daily living conditions, and access to quality
health services that are affordable) is of crucial importance
for effective primary stroke prevention.77,78 Addressing
social determinants of health requires the involvement of a
wide range of stakeholders both within and beyond the
health sector and at all levels of government (figure 2).2,77
Actions to improve stroke prevention come at a cost.
With already overstretched health budgets, even in HICs,
www.thelancet.com/public-health Vol 7 January 2022
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sustainable funding is an issue. One of the most
promising strategies to secure such funding is to reinvest
revenues from taxation on unhealthy products (eg, tobacco,
sugary drinks, alcohol, and salt in processed food)38,78–84
and the money saved from preventing stroke back into
health services and preventive strategies.72 This strategy is
important as reduced consumption of these unhealthy
foods has been shown to be beneficial for stroke,
cardiovascular disease, and overall health at the population
level. Although it is widely acknowledged that prevention
is better than cure, even HICs allocate less than 2–3% on
average of their health spending to public health and
prevention activities,85 and there is also evidence of
substantial underfunding of stroke-related research.86
Governments have a leading role in the implementation
of proven effective primary stroke prevention strategies
and should be transparent about the proportion of health
budgets that are focused on prevention.
Politicians and policy makers should realise that,
without urgent improvement in the primary prevention
of stroke and other major NCDs, the sustainability of the
whole health system could soon be in question. Only by
combining with other interventions for NCD prevention
will stroke prevention inventions be fully impactful.71 The
Global Alliance for Chronic Diseases is a good example
of such an integrative approach. Several reports show the
effectiveness of population-wide primary prevention
strategies in selected populations of Finland,61 Japan,62
and the USA.63

Innovative dissemination for substantial
implementation and impact
The establishment of the global Stroke Control,
Observatory, and Reduction Ecosystem (gSCORE;
appendix p 25)11,87 will be key to engage all stakeholders in
society to: address key environmental factors via policy
change (eg, the social determinants of health and making
default choices healthy); enhance stroke awareness
through key community influencers who can deliver
culturally tailored messages with strategies, such as
using social media (ie, social media influencers) and the
arts (ie, music, comedy, film, and television); address
motivation, self-efficacy, and self-management skills; and
empower the stroke commissioners to be the champions
and advocates of ensuring rigorous implementation and
evaluation across the globe.
The gSCORE, using the WHO Global Action Plan for
NCDs, is planned to operate at country, regional, and
global levels in collaboration with relevant policy makers
and implementation partners, including national and
regional stroke, neurology, cardiovascular disease, and
NCD organisations and relevant alliances.

Conclusions and future directions
This Health Policy paper provides estimates of the global
cost of stroke and evidence-based pragmatic solutions on
strategies for primary stroke prevention, especially in
www.thelancet.com/public-health Vol 7 January 2022

Search strategy and selection criteria
We searched MEDLINE, Embase, Google Scholar, Google,
and the Cochrane Library with the keywords in the title or
abstract: “stroke”, “cerebrovascular disease”, “isch(a)emic
stroke”, “intracerebral h(a)emorrhage”, “subarachnoid h(a)
emorrhage”, “transient isch(a)emic attack”, or “cardiovascular
disease” AND “prevention”, “cost”, “guidelines”, “awareness”,
“tax or taxation”, “trial”, “policy”, “legislation”, “mHealth”,
“eHealth”, “polypill”, “roadmap”, “incidence”, “prevalence”,
“mortality”, “burden”, or “outcomes” for research published
between Jan 1, 1980, and May 15, 2021, in English. We also
searched websites of medical societies and stroke experts for
additional stroke prevention guidelines. We focused our
searches on population-based studies and guidelines related
to primary stroke prevention published since Jan 1, 2011.
Additionally, we manually searched the reference lists of
relevant publications and consulted with experts in stroke,
cardiovascular disease, and other relevant stakeholders to
complement the electronic searches.

LMICs. The proffered key solutions are targeted at
reducing the occurrence of stroke and preventing
economic losses from stroke through primary prevention
across the life course. As many lifestyle habits are set early
in life, culturally appropriate education about healthy
lifestyles should be incorporated into standard education
curricula, started early in life with reinforcement across
the lifespan, and incorporate families. These preventive
strategies should be complemented by adequate stroke
education campaigns that consider cultural and subcultural
differences, ethnicities, beliefs, geographical differences,
and risk of stroke across the lifetime.
For an effective effort, there is a need for synergy
between health-care providers, government and nongovernment agencies, industry, academic organisations,
opinion leaders in society, and individuals. An approach
that integrates strategies aimed at primary stroke
prevention (population-wide and targeted strategies
towards individuals with any level of increased stroke
risk) with strategies aimed at prevention of other NCDs
is most likely to be successful as many risk factors are
shared between stroke and other NCDs. Establishing a
global chronic disease prevention initiative with stroke as
a major focus has also been suggested.88
As many stroke risk factors are common to other major
NCDs, such as ischaemic heart disease, type 2 diabetes,
renal disease, dementia, and some types of cancer, it is
expected that the worldwide implementation of the
solutions will not only halve the burden of stroke but also
substantially reduce the burden from other major NCDs.
This co-benefit would not only save millions of lives
around the globe but could also have a substantial
economic impact. The development of primary stroke
prevention guidelines for LMICs is urgently required.
The audience for future primary stroke prevention

For more on the Global Alliance
for Chronic Diseases see
http://www.gacd.org/about
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guidelines in HICs and LMICs should be broadened
since many primary stroke prevention interventions
require intersectoral funding, policy initiatives, and buyin from the population. Additional research is required
to develop integrative, culturally appropriate, and
population-specific eHealth technologies for effective
primary stroke prevention, including digital decisionmaking tools for clinicians and community health
workers, and to establish the best balance between
various primary stroke prevention strategies to maximise
cost-effectiveness and minimise inequalities.
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